REG - Eco Animal Health Gp - Notice of General Meeting and Notice of Results

ECO Animal HealthAnnouncement

08/07/2025 16:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250708:nRSH2324Qa&default-theme=true

RNS Number : 2324Q  Eco Animal Health Group PLC  08 July 2025

8 July 2025

 

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

Share Repurchase, Notice of General Meeting and Notice of Results

 

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health
company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, announces that it is today posting to
shareholders a circular (the "Circular") which contains a notice of general
meeting (the "Notice") and a form of proxy. The General Meeting will be held
on 21 August 2025, to seek shareholders' approval for the Board to make
limited on market purchases of the Company's ordinary shares of 5 pence each
("Ordinary Shares").

 

On 9 February 2025, the Company announced the disposal of certain non-core
product lines. The board stated that it intends to use a portion the proceeds
from the sale to purchase Ordinary Shares in the market to cover possible
future vesting of employee share-based incentives including share options,
long term incentive plans and the deferred bonus scheme.

 

Copies of the Circular, Form of Proxy and the Notice will be made available on
the Company's website at www.ecoanimalhealth.com
(http://www.ecoanimalhealth.com) .

 

The Company also announces that it will issue its audited financial results
for the year ended 31 March 2025 on 14 July 2025.

 

David Hallas, CEO, and Christopher Wilks, CFO, will host an in-person
presentation and Q&A session for analysts at 11:00 BST on the day of
results. There will be a dial-in option for those unable to attend in person.

 

For further information about the analyst presentation, please contact
 ecoanimalhealth@icrhealthcare.com.

In addition, David Hallas and Christopher Wilks will conduct a live online
presentation of the results at 14:00 BST on 14 July 2025.  This event is open
to all existing and potential shareholders and registration is free. Questions
can be submitted during the presentation and will be addressed at the end of
it.

To register for the event, please click here
(https://www.equitydevelopment.co.uk/news-and-events/eco-animal-health-fy-results-investor-presentation-14th-july-2025)
.

For further information please contact:

 

 ECO Animal Health Group plc                                    020 8447 8899

 David Hallas (CEO)

 Christopher Wilks (CFO)

 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Phil Davies

 Sam Butcher

 Investec (Joint Broker)                                        020 7597 5970

 Gary Clarence

 Lydia Zychowska

 Equity Development                                             020 7065 2692

 Hannah Crowe

 Matt Evans

 ICR Healthcare (Financial PR)                                  020 3709 5700

 Mary-Jane Elliott                                              ecoanimalhealth@icrhealthcare.com

 Jessica Hodgson

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.

Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.

Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGZGGNKRDGKZM